Free Newsletter
SPOTLIGHT: Levaquin approval expanded
Free newsletter via e-mail
Tools
SPOTLIGHT ON... Levaquin approval expanded
Johnson & Johnson's short-course antibiotic Levaquin got the FDA's approval as a treatment for stubborn urinary-tract infections and kidney infection. Release
More stories about FDA approval
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: